- Home
- ARCT
as 11-15-2024 4:00pm EST
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 602.7M | IPO Year: | N/A |
| Target Price: | $65.00 | AVG Volume (30 days): | 400.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.93 - $45.00 | Next Earning Date: | 11-07-2024 |
| Revenue: | $160,399,000 | Revenue Growth: | -45.85% |
| Revenue Growth (this year): | 13.02% | Revenue Growth (next year): | 5.58% |
Stock Insider Trading Activity of Arcturus Therapeutics Holdings Inc. (ARCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chivukula Pad | ARCT | Chief Scientific Officer & COO | Oct 15 '24 | Sell | $20.76 | 12,000 | $249,121.20 | 435,334 |
Latest Arcturus Therapeutics Holdings Inc. News
ARCT Breaking Stock News: Dive into ARCT Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
MT Newswires
6 days ago
Arcturus Therapeutics Gets FDA Greenlight for H5N1 Pandemic Flu Vaccine Trial
Business Wire
6 days ago
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
Simply Wall St.
8 days ago
Arcturus Therapeutics Holdings Third Quarter 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
9 days ago
Q3 2024 Arcturus Therapeutics Holdings Inc Earnings Call
GuruFocus.com
9 days ago
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call Highlights: Strategic Advances ...
Zacks
10 days ago
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
10 days ago
Arcturus Therapeutics: Q3 Earnings Snapshot
Compare ARCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARCT Arcturus Therapeutics Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.